Kyverna Locks In Commercial Manufacturing for Miv-cel Ahead of BLA Completion
KYTX has more than doubled off its 52-week low of $2.8.
Summary
Kyverna entered a five-year clinical and commercial supply agreement with ElevateBio for its lead CAR-T therapy miv-cel, replacing a prior development-only deal. The agreement secures manufacturing capacity ahead of the planned BLA completion in Q4 2026 and potential commercial launch in stiff person syndrome.
Key Events · M&A and Partnerships · KYTX
-
Commercial Manufacturing Deal Signed
On July 23, 2026, Kyverna and ElevateBio signed a Clinical and Commercial Supply Agreement, replacing the prior development-only arrangement. The new deal covers both U.S. commercial and global clinical supply of miv-cel.
-
Minimum Purchase Commitments
To secure dedicated manufacturing capacity, the agreement requires Kyverna to order minimum quantities of miv-cel in certain calendar years and/or following FDA approval.
-
Five-Year Term with Renewals
The initial term runs for five years, with automatic renewals for successive one-year periods unless either party terminates with advance notice or for an uncured material breach.
-
BLA Completion on Track for Q4 2026
Kyverna reiterated its timeline to complete the rolling BLA submission for miv-cel in stiff person syndrome in the fourth quarter of 2026, a milestone that could make it the first FDA-approved CAR-T for an autoimmune disease.
Analysis · KYTX · Life Sciences
Kyverna has replaced its earlier development-stage manufacturing agreement with a comprehensive clinical and commercial supply contract with ElevateBio. This move secures production capacity for miv-cel just as the company approaches the finish line on its rolling BLA submission for stiff person syndrome, expected in Q4 2026. The inclusion of minimum purchase commitments underscores management's confidence in both approval and launch readiness. For a pre-revenue biotech with a $450M market cap, locking in commercial-scale manufacturing is a critical de-risking step that directly supports the transition to a commercial-stage company.
At the time of this filing, KYTX was trading at $7.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $450.5M. The 52-week trading range was $2.80 to $13.67. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.